Find Afoxolaner manufacturers, exporters & distributors on PharmaCompass

Afoxolaner

Afoxolaner

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

10 API Suppliers, 1 NDC API, 10 Listed Suppliers

DOSSIERs // Finished Dosage Formulations

9 Dossiers, 9 Canada

MARKET PLACE

2 APIs

2 APIs

PATENTS

4 Health Canada Patents

4 Health Canada Patents

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 2 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

689.00

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1093861-60-9, Afoxolaner [usan], 02l07h6d0u, Afoxolaner (usan), 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide

Molecular Formula

C₂₆H₁₇ClF₉N₃O₃

Molecular Weight

625.9 g/mol

InChI Key

OXDDDHGGRFRLEE-UHFFFAOYSA-N

FDA UNII

02L07H6D0U

1 2D Structure

Afoxolaner

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

2.1.2 InChI

InChI=1S/C26H17ClF9N3O3/c27-15-8-13(7-14(9-15)25(31,32)33)23(26(34,35)36)10-20(39-42-23)18-5-6-19(17-4-2-1-3-16(17)18)22(41)37-11-21(40)38-12-24(28,29)30/h1-9H,10-12H2,(H,37,41)(H,38,40)

2.1.3 InChI Key

OXDDDHGGRFRLEE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1C(=NOC1(C2=CC(=CC(=C2)Cl)C(F)(F)F)C(F)(F)F)C3=CC=C(C4=CC=CC=C43)C(=O)NCC(=O)NCC(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

02L07H6D0U

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(5-(3-chloro-5-(trifluoromethyl)-phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2- Oxo-2-((2,2,2-trifluoroethyl)amino)ethyl-1-naphthalenecarboxamide

2.3.2 Depositor-Supplied Synonyms

1. 1093861-60-9

2. Afoxolaner [usan]

3. 02l07h6d0u

4. Afoxolaner (usan)

5. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

6. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide

7. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide

8. Afoxolaner [usan:inn]

9. Unii-02l07h6d0u

10. Nexgard

11. Afoxolaner [mi]

12. Afoxolaner [inn]

13. C26h17clf9n3o3

14. Schembl119580

15. Afoxolaner [green Book]

16. Chembl2219412

17. Dtxsid50148921

18. Bcp21108

19. Ex-a3267

20. Afoxolaner [ema Epar Veterinary]

21. Hy-16974

22. Nexgard Spectra Conponent Afoxolaner

23. Cs-0013215

24. Afoxolaner Conponent Of Nexgard Spectra

25. J3.498.573a

26. D10361

27. Q21051346

28. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

29. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

30. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl(-n- (2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl(naphthalene-1-carboxamide

31. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)naphthalene-1-carboxamide

32. 4-[(5r)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

2.4 Create Date

2009-02-23

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₁₇ClF₉N₃O₃
Molecular Weight	625.9 g/mol
XLogP3	6.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	6
Exact Mass	625.0814726 g/mol
Monoisotopic Mass	625.0814726 g/mol
Topological Polar Surface Area	79.8 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	1040
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). One treatment kills ticks for up to one month.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Treatment of demodicosis (caused by Demodex canis).

Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

5 Pharmacology and Biochemistry

5.1 ATC Code

QP53BE01